NCT00586651 2015-10-08
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Icahn School of Medicine at Mount Sinai